Loading...
StocksRunner logo
 
 
BioAtla
3.67
-0.95%
 
BCAB BioAtla
Last Price
Change
3.67
 
-0.95%
 
 
 

 
Sentiment
 
 

3.55

2.49

4.24

2.97

 
 
1m
3m
6m
1y
 

Summary

BioAtla (BCAB) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 

Risk Level

 
StocksRunner
 

BioAtla (BCAB) has Extreme Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

3.00
 
 

Future

×
 

Future

4.00
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
75%
100%
NA
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
75%
0%
Positive
Negative
3 out of 4
events present
0 out of 4
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Investors Activity
3 Weeks Ago
3.29
-6.41%
 
Buy Rating
3 Weeks Ago
3.87
+5.45%
 
Buy Rating
2 Month Ago
3.63
-3.97%
 
Top Headlines

bioatla (bcab) investor presentation - slideshow.

Thu May 18, 2023

Activity

jmp securities reiterates bioatla (bcab) outperform recommendation. fintel reports that on may 15 2023 jmp securities reiterated coverage of bioatla (nasdaq:bcab) with a outperform recommendation.

Tue May 16, 2023

Potential

hc wainwright & co. reiterates bioatla (bcab) buy recommendation. fintel reports that on may 15 2023 hc wainwright &. co. reiterated coverage of bioatla (nasdaq:bcab) with a buy recommendation.

Mon May 15, 2023

Rating

ef hutton maintains bioatla (bcab) buy recommendation. fintel reports that on april 17 2023 ef hutton maintained coverage of bioatla (nasdaq:bcab) with a b

Wed Apr 19, 2023

Rating

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily BCAB alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

BCAB BioAtla

Last Price
3.67
Change
-0.95%
 
 

Most Trending

 

+4.26%

 
 
 
 

-0.83%

 
 
 

Summary

BioAtla (BCAB) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time

 
 
3.55
2.49
4.24
2.97
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
NA
100%
On Track
On Track
On Track
 
75%
0%
Positive
Negative
3 out of 4
events present
0 out of 4
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

3.00
 
 

Future

×
 

Future

4.00
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

BioAtla (BCAB) has Extreme Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Investors Activity
3 Weeks Ago
3.29
-6.41%
 
Buy Rating
3 Weeks Ago
3.87
+5.45%
 
Buy Rating
2 Month Ago
3.63
-3.97%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily BCAB Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines